Lower Gastrointestinal Kaposi Sarcoma in HIV/AIDS: A Diagnostic Challenge.
Early detection
Endoscopic diagnosis
HIV/AIDS
Kaposi sarcoma
Journal
Gastrointestinal tumors
ISSN: 2296-3774
Titre abrégé: Gastrointest Tumors
Pays: Switzerland
ID NLM: 101644585
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
16
01
2019
revised:
01
04
2019
entrez:
12
10
2019
pubmed:
12
10
2019
medline:
12
10
2019
Statut:
ppublish
Résumé
Gastrointestinal Kaposi sarcoma (GI-KS) is the most common extra-cutaneous site of KS in HIV/AIDS, and the majority (75%) of affected patients are asymptomatic. GI-KS rarely occurs in the absence of cutaneous lesions. Opportunistic GI infections in HIV/AIDS and GI-KS can present with similar symptoms especially diarrhea, creating a diagnostic challenge. We present a 46-year-old homosexual male with a medical history of HIV/AIDS and neurosyphilis, who presented with 2 weeks of nonbloody diarrhea and abdominal discomfort. He was initially worked up for infectious diarrhea, initiated on highly active anti-retroviral (HAART) and supportively managed with rehydration therapy and analgesia. However, his clinical symptoms did not improve, necessitating abdomen/pelvic CT scan which revealed extensive recto-sigmoid colon thickening and pelvic lymphadenopathy. Due to a high suspicion of malignancy, diagnostic endoscopy and biopsy were done which showed colonic KS. He was treated with intravenous pegylated doxorubicin in addition to HAART which evidently resulted in significant clinical and radiological improvement. The diagnosis of GI-KS could be challenging in the presence of overlapping features with opportunistic GI infections and the absence of cutaneous manifestations of KS because clinicians tend to focus more on infectious etiology. We suggest that clinicians should consider GI-KS in the differential diagnosis of patients with HIV/AIDS that present with diarrhea and other nonspecific abdominal symptoms. Early endoscopic evaluation with biopsy could help to ensure the timely diagnosis and management of GI-KS and ultimately improve outcomes.
Identifiants
pubmed: 31602377
doi: 10.1159/000500140
pii: gat-0006-0051
pmc: PMC6738214
doi:
Types de publication
Case Reports
Langues
eng
Pagination
51-55Informations de copyright
Copyright © 2019 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors do not have any conflicts of interest to disclose or any financial disclosures.
Références
Gastroenterol Hepatol (N Y). 2010 Jul;6(7):459-62
pubmed: 20827371
HIV Med. 2008 Jul;9(6):336-88
pubmed: 18705759
J Clin Oncol. 2014 Feb 10;32(5):409-14
pubmed: 24378415
J Gastrointestin Liver Dis. 2013 Dec;22(4):441-5
pubmed: 24369327
Gastrointest Endosc Clin N Am. 1998 Oct;8(4):889-911
pubmed: 9730938
Int J Infect Dis. 2015 Oct;39:110-5
pubmed: 26376222
J Natl Cancer Inst. 2010 Jun 2;102(11):784-92
pubmed: 20442214
Eur Rev Med Pharmacol Sci. 2013 Sep;17(17):2354-65
pubmed: 24065230
PLoS One. 2012;7(11):e46967
pubmed: 23226197
J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30
pubmed: 11078759
World J Gastrointest Pharmacol Ther. 2015 Aug 6;6(3):89-95
pubmed: 26261737
Science. 1994 Dec 16;266(5192):1865-9
pubmed: 7997879